Table 1 of
Zou, Mol Vis 2021; 27:1-16. Table 1 of
Zou, Mol Vis 2021; 27:1-16.
Table 1. Detection of RB1 mutations reported from different countries of East Asia.
| Authors | Countries | Methods | Samples | Total number of RB patients | Total detection rates of mutations | Detection rates of mutations in bilateral RB |
|---|---|---|---|---|---|---|
| Takashi Shimizu et al.,1994 [15] | Japan | PCR-SSCP and direct genomic sequencing | Tumors | 24 | 58% | 50% |
| Mitsuo V. Kato et al., 1994 [16] | Japan | Southern blotting and RT–PCR | Tumor tissues and skin biopsies | 10 | 40% | 40% |
| SH Seo et al., 2012 [17] | South Korea | RB1 Exome sequencing and MLPA | Peripheral blood | 21 | 71.4% | 93.8% |
| Guangyin Cheng et al., 2013 [18] | China | PCR-SSCP-DNA sequencing | Peripheral blood and tumor tissues | 47 | 21% | 70% |
| Ming-yan He et al., 2014 [19] | China | DNA sequencing and MLPA | Peripheral blood | 85 | 47.1% | 92.3% |
| Xiaoping Lan et al., 2020 [20] | China | Sanger sequencing and MS-MLPA | Peripheral blood | 180 | 41.7% | 90.3% |